COMMUNIQUÉS West-GlobeNewswire

Ossur Hf : Transactions in relation to share buyback program

06/06/2017 - 18:00

Announcement from Össur hf. No. 43/2017 Reykjavík, 05 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]

Issuance of new shares to the Finnish Innovation Fund Sitra pursuant to the financing arrangement announced on 21 July 2016

06/06/2017 - 18:00

Company announcement, Helsinki, 6 June 2017 at 7:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

MITHRA SIGNS EXCLUSIVE AGREEMENT FOR TIBELIA® IN CANADA

06/06/2017 - 17:45

PRESS RELEASE Mithra signs Exclusive agreement for Tibelia® in Canada Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada Marketing authorization process is ongoing Tibelia® already [...]

Refixia® (nonacog beta pegol; N9-GP) approved in the EU

06/06/2017 - 16:55

Company Announcement No 42/2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting

06/06/2017 - 16:30

Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefing on Saturday, June 10 from 2 - 4 p.m. PDT DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in medical technology, today [...]

Medtronic SureTune(TM)3 Receives Health Canada Licence for Deep Brain Stimulation Therapy

06/06/2017 - 16:00

DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology [...]

AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research

06/06/2017 - 15:00

AbCellera announces a project with Sanofi Pasteur to apply its human antibody discovery and immune profiling technology for the research and development of next-generation influenza vaccines. VANCOUVER, British Columbia [...]

Annual General Meeting held

06/06/2017 - 14:37

Navamedic ASA has today, 6 June 2017, held an annual general meeting. All resolutions were made in accordance with the board's/nomination committee's proposals. The minutes from the general meeting is attached hereto [...]

Novo Nordisk A/S - Share repurchase programme

06/06/2017 - 14:25

Bagsværd, Denmark, 06 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

06/06/2017 - 13:30

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi ® (palonosetron hydrochloride) in Canada Lugano, Switzerland and Pickering, Canada, June 6, 2017 - [...]

Verona Pharma plc : Holding(s) in Company

06/06/2017 - 13:29

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please [...]

uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer

06/06/2017 - 13:00

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Steven L. Zelenkofske, D.O., as Chief [...]

Verona Pharma plc : Holding(s) in Company

06/06/2017 - 12:54

For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting [...]

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

06/06/2017 - 11:00

Heidelberg, Germany, June 6, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Company [...]

Helsinn: First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Dr Sarah A Buckley

06/06/2017 - 10:30

First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington Lugano, Switzerland, [...]

Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for Prediction of Acute Kidney Injury Cleared, Available in Europe

06/06/2017 - 08:30

New test expands Ortho's VITROS(R) menu RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the [...]

Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting

06/06/2017 - 07:15

Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel [...]

Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label

06/06/2017 - 07:15

Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna [...]

Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting

06/06/2017 - 07:01

Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that [...]